Genentech's Fenebrutinib Achieves Unmatched Phase III Success as the Potential First and Sole BTK Inhibitor for Relapsing and Primary Progressive Multiple Sclerosis

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: Nov 10 2025

0mins

Source: Yahoo Finance

Fenebrutinib Efficacy in RMS: The first pivotal study (FENhance 2) demonstrated that fenebrutinib significantly reduced relapses in patients with relapsing multiple sclerosis (RMS) compared to teriflunomide.
Fenebrutinib in PPMS: In a separate study (FENtrepid), fenebrutinib was shown to be non-inferior to Ocrevus in slowing disability progression in patients with primary progressive multiple sclerosis (PPMS).
Upcoming Data and Regulatory Submission: Full data from both studies will be presented at medical meetings, and a regulatory submission will be considered after the second RMS study (FENhance 1) results are available in 2026.
Mechanism of Action: Fenebrutinib targets B cells and microglia to control inflammation and chronic damage, potentially addressing key unmet needs in multiple sclerosis treatment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.